RCE Technologies, Inc.

Businessfiled

RCE Technologies, Inc. operates in Biotechnology, based in CARLSBAD.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

RCE Technologies, Inc. has raised $5.8M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.1M on 2023-11-20.

Most recent recorded round closed around 2023-11-20.

Filings read as a recurring offering program rather than a clean venture-stage ladder — interpret stage labels and step-ups with that in mind.

Valuation (modeled)modeled

Provath models RCE Technologies, Inc. at approximately $15M (range $1.5M–$46M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.02× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Within the normal band (102% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 2 months.

Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 1.8× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 46% of Biotechnology peers (4293 compared).

Modeled value ranks above 24% of those peers.

Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.

Recurring-offering pattern: stage-based valuation has lower applicability.